Search results for "From ACP Journal Club"
Review: In diabetes, intensive and standard glycemic control do not differ for end-stage kidney disease or death
The review suggests that treating diabetes with strict glycemic control does not reduce mortality or cardiovascular risk or slow progression of kidney disease, and the results question whether strict glycemic control for preventing any complications is warranted, ACP Journal Club authors wrote.
https://diabetes.acponline.org/archives/2017/11/10/8.htm
10 Nov 2017
In abstinent adults with type 2 diabetes, a daily glass of wine (vs mineral water) improved cardiometabolic factors
Drinking red wine, rather than mineral water, with dinner every night for 2 years was associated with improvements in cholesterol markers in patients in Israel. A group assigned to white wine did not show significant differences on these markers from the water group.
https://diabetes.acponline.org/archives/2016/03/11/6.htm
11 Mar 2016
Review: Intensive blood pressure control reduces retinopathy in diabetes
Intensive control of blood pressure reduced incidence of retinopathy, but not progression of established retinopathy, in patients with type 1 or 2 diabetes, according to an analysis of 15 randomized controlled trials.
https://diabetes.acponline.org/archives/2015/07/10/5.htm
10 Jul 2015
In type 2 diabetes treated with high-dose insulin, liraglutide reduced HbA1c
The hypoglycemia rate was higher in the first month after initiation of liraglutide, but the overall hypoglycemia rate over the 6-month follow-up was similar in liraglutide and placebo patients.
https://diabetes.acponline.org/archives/2016/11/11/5.htm
11 Nov 2016
In type 1 diabetes, adding liraglutide to insulin increased hypoglycemia and hyperglycemia with ketosis
The study authors concluded that the negative effects observed would limit clinical use of liraglutide in patients with type 1 diabetes.
https://diabetes.acponline.org/archives/2017/01/13/6.htm
13 Jan 2017
Semaglutide reduced a composite of CV events at two years in patients with type 2 diabetes and high CV risk
Semaglutide, a new once-weekly glucagon-like peptide-1 (GLP-1) analogue, reduced cardiovascular (CV) events compared to placebo, according to a manufacturer-sponsored study.
https://diabetes.acponline.org/archives/2017/02/10/7.htm
10 Feb 2017
Review: Sulfonylureas are associated with overall mortality and CV events vs other antihyperglycemics
A review looked at randomized trials that compared mortality rates among patients taking sulfonylureas versus several other classes of hypoglycemic drugs.
https://diabetes.acponline.org/archives/2017/05/12/6.htm
12 May 2017
Review: Metformin is linked to reduced mortality in type 2 diabetes with comorbid CKD and CHF
The included studies focused on metformin use in patients with chronic kidney disease (CKD), congestive heart failure (CHF), chronic liver disease (CLD), or older age.
https://diabetes.acponline.org/archives/2017/05/12/7.htm
12 May 2017
In patients with type 2 diabetes and CVD, empagliflozin reduced incident or worsening nephropathy at 3.1 y
A subanalysis of a trial of empagliflozin for patients with cardiovascular disease (CVD) found lower rates of nephropathy in those randomized to empagliflozin rather than placebo.
https://diabetes.acponline.org/archives/2016/11/11/7.htm
11 Nov 2016
Bariatric surgery improved HbA1c more than intensive medical therapy in obese patients with uncontrolled type 2 DM
Longer-term outcomes show that adding Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy to intensive medical therapy enabled more obese, type 2 diabetes patients to maintain glycemic control.
https://diabetes.acponline.org/archives/2014/09/12/6.htm
12 Sep 2014